Ivabradine Hydrochloride Patent Expiration
Ivabradine Hydrochloride is Used for treating heart failure in humans. It was first introduced by Amgen Inc
Ivabradine Hydrochloride Patents
Given below is the list of patents protecting Ivabradine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Corlanor | US7361649 | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Feb 22, 2026 | Amgen Inc |
| Corlanor |
US7361649 (Pediatric) | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Aug 22, 2026 | Amgen Inc |
| Corlanor | US7361650 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Feb 22, 2026 | Amgen Inc |
| Corlanor |
US7361650 (Pediatric) | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Aug 22, 2026 | Amgen Inc |
| Corlanor | US7867996 | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Dec 12, 2026 | Amgen Inc |
| Corlanor |
US7867996 (Pediatric) | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Jun 12, 2027 | Amgen Inc |
| Corlanor | US7879842 | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Feb 22, 2026 | Amgen Inc |
| Corlanor |
US7879842 (Pediatric) | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | Aug 22, 2026 | Amgen Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Ivabradine Hydrochloride Generics
Several generic applications have been filed for Ivabradine Hydrochloride. The first generic version for Ivabradine Hydrochloride was by Ingenus Pharmaceuticals Llc and was approved on Dec 30, 2021. And the latest generic version is by Zydus Pharmaceuticals Usa Inc and was approved on Nov 29, 2023.
Given below is the list of companies who have filed for Ivabradine Hydrochloride generic.
1. ANNORA PHARMA
Annora Pharma Private Ltd has filed for 2 different strengths of generic version for Ivabradine Hydrochloride. Given below are the details of the strengths of this generic introduced by Annora Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE | tablet | Prescription | ORAL | AB | Oct 5, 2022 |
| EQ 7.5MG BASE | tablet | Prescription | ORAL | AB | Oct 5, 2022 |
2. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Ivabradine Hydrochloride. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE | tablet | Prescription | ORAL | AB | Nov 29, 2023 |
| EQ 7.5MG BASE | tablet | Prescription | ORAL | AB | Nov 29, 2023 |
3. INGENUS PHARMS LLC
Ingenus Pharmaceuticals Llc has filed for 2 different strengths of generic version for Ivabradine Hydrochloride. Given below are the details of the strengths of this generic introduced by Ingenus Pharms Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 7.5MG BASE | tablet | Prescription | ORAL | AB | Dec 30, 2021 |
| EQ 5MG BASE | tablet | Prescription | ORAL | AB | Dec 30, 2021 |